Ralliant (NYSE:RAL) Updates Q2 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.580-0.640 for the period, compared to the consensus estimate of 0.520. The company issued revenue guidance of $540.0 million-$556.0 million, compared to the consensus revenue estimate of $529.0 million. Ralliant also updated its FY 2026 guidance to 2.530-2.690 EPS.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Barclays upped their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Royal Bank Of Canada upped their target price on shares of Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a report on Wednesday. Oppenheimer lifted their price target on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.60.

Ralliant Stock Up 3.8%

RAL stock opened at $61.41 on Thursday. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $62.35. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 0.58. The stock has a market capitalization of $6.87 billion and a price-to-earnings ratio of -5.61. The business’s fifty day moving average price is $44.88 and its two-hundred day moving average price is $47.32.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Ralliant will post 2.37 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is 10.20%.

Insider Activity

In related news, SVP Karen M. Bick sold 5,485 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the sale, the senior vice president owned 46,756 shares of the company’s stock, valued at $2,104,020. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Trading of Ralliant

Several institutional investors have recently added to or reduced their stakes in the stock. Palisade Asset Management LLC bought a new stake in shares of Ralliant in the 3rd quarter valued at $26,000. BOKF NA bought a new position in Ralliant in the third quarter worth approximately $29,000. Wilmington Savings Fund Society FSB bought a new position in Ralliant in the third quarter worth approximately $30,000. EverSource Wealth Advisors LLC acquired a new stake in Ralliant in the second quarter valued at approximately $39,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Ralliant during the second quarter valued at approximately $43,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.